The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia
Xinyu Li(Tianjin University), Yubin Ge(Wayne State University), Jay Yang(Boston Children's Hospital), Sijana H. Dzinic(Wayne State University), Regan Miller(Oakland University), Tristan Knight(Wayne State University), Kathryn White(Wayne State University), Lijing Zhao(Hebei Medical University), Holly Edwards(Wayne State University), Y. Lynn Wang(Southwest Medical University), Lisa Polin(Wayne State University), Hai Lin(Jilin University), Gerard J. Madlambayan(University of Rochester), Juiwanna Kushner(Wayne State University), Guan Wang(First Hospital of China Medical University), Jeffrey W. Taub(Wayne State University), Katie Hege(Wayne State University), Yongwei Su(Jilin University)
Cited by 53
Related Papers
Alginate hydrogels as synthetic extracellular matrix materials
|Biomaterials|1999|2.3k
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
|The Lancet Oncology|2010|586
Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2012|217
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
|Signal Transduction and Targeted Therapy|2020|216